The use of drugs for cardioversion of recent onset atrial fibrillation and flutter: Focus on ibutilide

Drugs and Aging

Volumn 12, Issue 6, 1998, Pages 461-476

  Obel, Owen A ^a   Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; IBUTILIDE FUMARATE;

ARTICLE; CARDIOMYOPATHY; CARDIOVERSION; DRUG CLASSIFICATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; STROKE; SYMPTOM; SYNCOPE; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; ELECTRIC COUNTERSHOCK; HUMANS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0031777363     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812060-00004     Document Type: Article

References (109)

1. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-22
2. Kitchin AH, Milne JS. Longitudinal survey of ischaemic heart disease in a randomly selected sample of older population. Br Heart J 1977; 39: 889-93
3. Gersh BJ. Epidemiology of atrial fibrillation and atrial flutter. In: DiMarco JP, Prystowsky EN, editors. Atrial arrhythmias: state of the art. Armonk (NY): Futura Publishing Company, Inc., 1996: 1-22
4. Bialy D, Lehmann MH, Schumacher DN, et al. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation [abstract]. J Am Coll Cardiol 1992; 19: 41A
5. Bellet S. Clinical disorders of the heart beat. Philadelphia: Lea & Febiger, 1963: 144-5
6. Waldo AL, Maclean WAH. Diagnosis and treatment of arrhythmias following open heart surgery - emphasis on the use of epicardail wire electrodes. New York: Futura Publishing, 1980
7. Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-6
8. Murgatroyd FD, Curzen NP, Aldergather J, et al. Clinical features and drug therapy in patients with paroxysmal atrial fibrillation: results of the CRAFT multi-center database [abstract]. J Am Coll Cardiol 1993; 21: 380A
9. Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990; 119: 996-1001
10. Serrano CVJ, Ramires JA, Mansur AP, et al. Importance of the time of onset of supraventricular tachyarrhythmias on prognosis of patients with acute myocardial infarction. Clin Cardiol 1995; 18: 84-90
11. Behar S, Zahavi Z, Goldbourt U, et al., SPRINT study group. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. Eur Heart J 1992; 13: 45-50
12. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995; 98: 476-84
13. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990; 15: 1279-85
14. Mathew JP, Parks R, Savino JS, et al. Atrial fibrillation following coronary artery bypass graft surgery. JAMA 1996; 267: 300-6
15. Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation 1996; 94: 390-7
16. Lauer MS, Eagle KA. Atrial fibrillation following cardiac surgery. In: Falk RH, Podrid PJ, editors. Atrial fibrillation: mechanisms and management. New York: Raven, 1992: 127-43
17. Rubin DA, Nieminski KE, Reed GE, et al. Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1987; 94: 331-5
18. Casthely PA, Yoganathan T, Komer C, et al. Magnesium and arrhythmias after coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1994; 8: 188-91
19. Mendes LA, Connelly GP, Davidoff R. Right artery coronary stenosis: an independent predictor of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 1995; 25: 198-202
20. Ali AS, Fenn NM, Zarowitz BJ, et al. Epidemiology of atrial fibrillation in patients hospitalised in a large hospital. Panminerva Med 1993; 35: 209-13
21. Murgatroyd FD, Camm AJ. Atrial arrhythmias. Lancet 1993; 341: 1317-22
22. Vaidya PN, Bhoseley PN, Rao DB. Tachyarrhythmias in old age. J Am Geriatr Soc 1976; 24: 412-4
23. Onundarson PT, Thorgeirsson D, Jonmudsson E. Chronic atrial fibrillation: epidemiologic features and 14 year follow-up: a case control study. Eur Heart J 1987; 8: 521-7
24. Cairns JA, Connely SJ. Nonrheumatic atrial fibrillation: risk of stroke and antithrombotic therapy. Circulation 1991; 84: 469-81
25. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22; 983-8
26. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987; 147: 1561-4
27. Lin HJ, Wolf PA, Benjamin EJ, et al. Newly diagnosed atrial fibrillation and acute stroke: the Framigham study. Stroke 1995; 26: 1527-30
28. Wolf PA, Dawber TR, Thomas HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973-7
29. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5
30. Petersen P, Madsen EB, Brun B, et al. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987; 18: 1098-100
31. Ott A, Breteler MM, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study: the Rotterdam study. Stroke 1997; 28: 316-21
32. Tunick PA, McElhinney L, Mitchell T, et al. The alternation between atrial flutter and atrial fibrillation. Chest 1992; 101: 34-6
33. Wood KA, Eisenberg SJ, Kalman JM, et al. Risk of thromboembolism in chronic atrial flutter. Am J Cardiol 1997; 79; 1043-7
34. Karnegis JN, Matoole JJ, Bjorling VG. Immediate improvement in left ventricular function after cardioversion of atrial flutter. Am J Cardiol 1989; 64: 1043-7
35. Kieney JR, Sacrez A, Facello A, et al. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992; 13: 1290-5
36. Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69: 1570-3
37. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med 1988; 85: 242-4
38. Van Den Berg MP, van Veldhuisen DJ, Crijns HJ, et al. Reversion of tachycardiomyopathy after beta-blocker [letter]. Lancet 1993; 341: 1667
39. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57: 563-70
40. Roberts SA, Diaz C, Nolan PE, et al. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol 1993; 72: 567-73
41. Alberts MJ, Bennett CA, Rutledge VR. Hospital charges for stroke patients. Stroke 1996; 27: 1825-8
42. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459-66
43. Scott WG, Scott WF. Ischaemic stroke in New Zealand: an economic study. N Z Med J 1994; 107: 443-6
44. Inoue H, Matsuo H, Takayanagi K, et al. Clinical and experimental studies of the effects of atrial extrastimulation and rapid pacing on atrial flutter cycle: evidence of macro-reentry with an excitable gap. Am J Cardiol 1981; 48: 623-31
45. Olgin JE, Kalman JM, Fitzpatrick AP, et al. Role of right atrial endocardial structures as barriers to conduction during human type 1 atrial flutter. Circulation 1995; 92: 1839-48
46. Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias - results and mechanisms. Circulation 1994; 89: 1074-89
47. Kalman JM, Olgin JE, Saxon LA, et al. Electrocardiographic and electrophysiologic characterisation of atypical atrial flutter in man: use of activation and entrainment mapping and implications for catheter ablation. J Cardiovasc Electrophysiol 1997; 8: 121-44
48. Wells JLJ, Maclean WAH, James TN, et al. Characterization of atrial flutter: studies in man after open heart surgery using fixed atrial electrodes. Circulation 1979; 60: 665-73
49. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther 1962; 140: 183-8
50. Konings K, Kirchhof CJHJ, Smeets JRLM, et al. High-density mapping of electrically induced atrial fibrillation in humans. Circulation 1994; 89: 1665-80
51. Wiener N, Rosenbleuth A. The mathematical formulation of the problem of conduction of impulses in a network of connected excitable elements, specifically in cardiac muscle. Arch Inst Cardiol Mex 1946; 16: 205-65
52. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68
53. Daoud EG, Bogun F, Goyal R, et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996; 94 (7): 1600-6
54. Shimizu A, Fukatani M, Tanigawa M, et al. Intra-atrial conduction delay and fragmented atrial activity in patients with paroxysmal atrial fibrillation. Jpn Circ J 1989; 53: 1023-30
55. Hashiba K, Tanigawa M, Fukatani M, et al. Electrophysiologic properties of atrial muscle in paroxysmal atrial fibrillation. Am J Cardiol 1989; 64 (20): 20J-23J
56. Allessie MA, Rensma PL, Brugada J, et al. Pathophysiology of atrial fibrillation. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Philadelphia: W.B. Saunders, 1990: 548-59
57. Henry WL, Morganroth J, Pearlman AS, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976; 53: 273-9
58. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12
59. Winkle RA, Mason JW, Griffin JC, et al. Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 1981; 102: 857-64
60. Anastasiou Nana MI, Anderson JL, Stewart JR, et al. Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect. Am Heart J 1987; 113: 1071-7
61. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111: 107-11
62. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16
63. Feld GK, Chen P, Nicod PH, et al. Possible atrial proarrhythmic effects of class 1c antiarrhythmic drugs. Am J Cardiol 1990; 66: 378-83
64. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262: 99-108
65. kr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation 1995; 91: 1799-806
66. Buchanan LV, Thompson DD, Hsu CL, et al. Antiarrhythmic and electrophysiologic effects of sublingual ibutilide fumarate. Drug Dev Res 1995; 34: 322-8
67. Naccarelli GV, Lee KS, Gibson JK, et al. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996; 78: 6-12
68. Ellenbogen KA, Wood MA, Stambler BS, et al. Conversion of atrial fibrillation and flutter by intravenous ibutilide: a multi-centre dose response study [abstract]. J Am Coll Cardiol 1994 Feb; Spec. iss.: 227A
69. DiMarco JP. Cardioversion of atrial flutter by intravenous ibutilide: a new class III antiarrhythmic agent [abstract]. J Am Coll Cardiol 1991; 17: 324A
70. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996; 28: 130-6
71. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613-21
72. Faniel R, Schoenfeld P. Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart J 1983; 4: 180-5
73. Anastasiou Nana MI, Levis GM, Moulopoulos SD. Amiodarone - application and clinical pharmacology in atrial fibrillation and other arrhythmias. Int J Clin Pharmacol Ther Toxicol 1984; 22: 229-35
74. Strasberg B. Intravenous amiodarone for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1991; 67: 325
75. Borgeat A, Goy JJ, Maendly R, et al. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986; 58: 496-8
76. Hellestrand KJ. Intravenous flecainide acetate for supraventricular tachycardias. Am J Cardiol 1988; 62 (6): 16D-22D
77. Goy JJ, Kaufmann U, Kappenberger LJ, et al. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol 1988; 62 (6): 38D-40D
78. Crijns HJ, Van Wijk LM, Van Gilst WH, et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988; 9: 634-8
79. Bianconi L, Boccadamo R, Pappalardo A, et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989; 64: 335-8
80. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63: 925-9
81. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722-7
82. Mostow ND, Vrobel TR, Noon D, et al. Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone. Am Heart J 1990; 120: 1356-63
83. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation - electrophysiological determinants of enhanced conversion efficacy. Circulation 1997; 96: 4298-306
84. Crijns HJGM, Van Gelder IC, Kingma JH, et al. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class I drug. Eur Heart J 1994; 15: 1403-8
85. Guo GB, Ellenbogen KA, Wood MA, et al. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol 1996; 27: 1083-9
86. Roden DM. Ibutilide and the treatment of atrial arrhythmias. Circulation 1996; 44: 1499-502
87. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803
88. Wang Q, Curran ME, Keating MT, et al. Positional cloning of a novel potassium gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genet 1996; 12: 17-23
89. Haverkamp W, Shenesa M, Borgeffe M, et al. Torsades de pointes. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Philadelphia: W.B. Saunders Co., 1995; 885-99
90. Waldo AL, Camm AJ, deRuyter H, et al., SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: survival with oral d-sotalol. Lancet 1996; 348: 7-12
91. Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23: 1535-40
92. Abascal VM, Dubrey S, Ochoa MR, et al. Electrical vs pharmacologic cardioversion in atrial fibrillation: does the atrium really care? [abstract] Circulation 1995; 92 Suppl. 1: 591
93. Manning WJ, Silverman DI, Katz SE, et al. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1995; 75: 624-6
94. Laupacis A, Albers G, Dunn M, et al. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102 Suppl. 4: 426S-33S
95. Fatkin D, Carroll G, Kuchar D, et al. Thromboembolic complications after pharmacologic cardioversion of atrial fibrillation. Aust N Z J Mod 1994; 24: 584
96. Senarath Yapa RS, Green GJ. Embolic stroke following cardioversion of atrial fibrillation to sinus rhythm with oral amiodarone therapy. Postgrad Med J 1990; 66: 410
97. Olshansky B. Management of atrial fibrillation after coronary artery bypass graft. Am J Cardiol 1996; 78: 27-34
98. Mattioni T, Denker S, Riggio D, et al. Efficacy and safety of intravenous ibutilide in the treatment of atrial flutter and atrial fibrillation following valvular or coronary artery bypass surgery [abstract]. Pacing Clin Electrophysiol 1997; 20 (4 Pt II): 1059
99. Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996; 77: 960-6
100. Buchanan LV, Turcotte UM, Kabell GG, et al. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1993; 33: 10-4
101. Resnekov L, McDonald L. Electroversion of lone atrial fibrillation and flutter including haemodynamic studies at rest and on exercise. Br Heart J 1971; 33: 339-50
102. Phillips BG, Bauman JL. Prescribing trends and pharmacoeconomic considerations in the treatment of arrhythmias: focus on atrial fibrillation and flutter. Pharmacoeconomics 1995; 7: 521-33
103. Brodsky MA, Allen BJ, Walker CM, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60: 572-5
104. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 72 (16): 75F-81F
105. Gosselink AT, Crijns HJ, Van Gelder IC, et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289-93
106. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82: 1932-9
107. Antman EM, Beamer AD, Cantillon C, et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15: 698-707
108. Crijns HJ, Van Gelder IC, Van Gilst WH, et al. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335-41
109. Disch DL, Greenberg ML, Holzberger PT, et al. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994; 120: 449-57